|Ted McCluskey (Board Director)|
Prior to consulting, Ted was Vice President of Clinical and Chief Medical Officer of Aviir for three years. He spent four years at Scios (a Johnson&Johnson Company) where he oversaw cardiovascular clinical development, including VEGF-121 and their lead product Natrecor. Prior to Scios, Ted was at Genentech for 8 years, overseeing clinical research on cardiovascular applications for TNKase, Bosentan, CathFlo Activase and for the anti-angiogenic ophthalmic agent Lucentis. He led the clinical development for the cardiovascular application of VEGF (vascular endothelial growth factor) by direct intra-coronary injection and has had extensive experience in both in-licensing and out-licensing projects. While at Genentech, he received additional training in Finance, Marketing and Management (Berkeley) and in Leadership and Strategy at an executive program at Harvard Business School.
Ted was trained as an interventional cardiologist (Cleveland Clinic) and served for several years on the faculty of the University of Cincinnati. Prior molecular biology and clinical cardiology training were at UCSF. His medicine residency was at Washington University in St. Louis as were his MD and PhD (Pharmacology). His undergraduate degree was in chemistry (with research honors) from Stanford.
Investment Interest: Biotech, Business Products & Services, Consumer Products & Services, Electronics & Instrumentation, Financial Services, Gaming, Healthcare Services, Industrial / Energy, Media & Entertainment, Medical Devices & Equipment, Network & Equipment, Retail/Distribution, Software, Telecom